Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals has completed its acquisition of 100% of the capital stock of Enobia Pharma, a private biopharmaceutical company.
Subscribe to our email newsletter
Enobia develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.
Goldman, Sachs & Co. acted as financial advisor to Alexion.
Ropes and Gray LLP acted as lead legal counsel to Alexion and Cassels Brock & Blackwell LLP acted as Canadian legal counsel to Alexion.